Cesar Rodriguez, MD
Articles
Community Care Provider’s Perspective on Administering Bispecifics in Patients with MM
Focused discussion on how patients receiving bispecific therapy for multiple myeloma are transitioned into and managed within the community setting.
Bispecifics in Multiple Myeloma: Transitioning Patient Care to the Community Setting
Expert panelists share insight on transitioning patients on bispecific therapy from an academic or specialty center to the community setting.
Long-Term Monitoring for CRS and AEs With Bispecific Therapy
Long-term considerations for the detection and treatment of CRS and other adverse events when managing patients with multiple myeloma.
Initial Monitoring for CRS and AEs in Patients With MM on Bispecifics
Expert perspectives on ensuring the early detection and treatment of CRS and other adverse events when initiating bispecific therapy in patients with multiple myeloma.
Multiple Myeloma: Addressing Financial Barriers to Bispecifics
Key opinion leaders in multiple myeloma management address barriers inherent in the selection and use of bispecifics.
Pharmacists’ Perspectives on Initiating Bispecific Therapy in Multiple Myeloma
Experts Scott A. Soefje, PharmD, and Kirollos S. Hanna, PharmD, share their perspectives on initial steps in initiating bispecific therapy for patients with multiple myeloma.
Administering Step-up and Treatment Doses of Bispecifics in Patients With MM
Frances A. Bell, NP, leads a conversation on key steps taken leading up to the initial administering of bispecific therapy in patients with multiple myeloma.
Where Do Bispecifics Fit in the Multiple Myeloma Treatment Paradigm?
Shared insight on the role bispecifics will play in multiple myeloma management as other novel agents and clinical trials continue to enter the landscape.
Treatment Considerations With Bispecifics in Multiple Myeloma
Panelists provide a broad-view perspective on established treatment pathways with bispecifics in multiple myeloma and the most prevalent challenges tied to this class of therapy.
Multiple Myeloma: Overview of an Evolving Treatment Landscape
Moderator Cesar Rodriguez, MD, spearheads a discussion on the current state of the multiple myeloma treatment paradigm with a focus on bispecifics in the multiply relapsed setting.
Management of Bispecific Toxicities and Final Thoughts on Treatments in MM
Closing out the panel discussion, experts review the management of bispecific-related toxicities and share their final thoughts on treating patients with multiple myeloma.
The Role of Belantamab Mafodotin and Its Impact on Future Treatment Options
Expert oncologists discuss Belantamab mafodotin, its recent withdrawal from the U.S. market, and the clinical implications of the DREAMM trials for patients with R/R multiple myeloma.
Rationale for Bispecific-Based Combinations in MM
Shared perspective on the potential role of ADCs, CAR T-cell therapy, and other agents in combination treatment with bispecifics for patients with multiple myeloma.
Treatment Selection of Bispecifics in Relapsed-Refractory MM
Focusing their discussion on clinical data in R/R multiple myeloma studies, panelists highlight current and emerging bispecific antibodies for treating patients that have progressed after multiple lines of therapy.
Treatment Approaches for Patients with Relapsed-Refractory MM
Expert panelists discuss treatment approaches for patient with multiple myeloma that have progressed and are relapsed and/or refractory (R/R).
Review of Patient Subgroups in Transplant-Ineligible NDMM
Oncology expert panelists review patient subgroup analyses for MAIA and SWOG0777 studies, investigating treatments for transplant-ineligible patients with newly diagnosed multiple myeloma.
Clinical Trials in Transplant-Ineligible NDMM
Expert panelists review clinical data from studies investigating treatment regimens for patients with NDMM that are transplant-ineligible.
Role of Transplant and Induction Therapies in NDMM
Expert perspectives on the role of transplants and induction therapy in patients with newly diagnosed multiple myeloma (NDMM).
Induction Regimen Options in Transplant-Eligible NDMM
Opening their discussion on transplant-eligible newly diagnosed multiple myeloma (NDMM), expert panelists review induction regimen options for patients.
